Key result
Novel antidiabetic agents show CV safety in type 2 diabetes, with liraglutide and empagliflozin demonstrating CV benefits.
Answers are grounded in this paper and cite their sources.
INTRODUCTION: Dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon-like peptide-1 (GLP-1) analogs and sodium-glucose cotransporter 2 (SGLT2) inhibitors are relatively new therapies for the treatment of type 2 diabetes mellitus. Given the high prevalence of cardiovascular complications in patients with type 2 diabetes and recent concerns questioning CV safety of newer antidiabetic medications, cardiovascular safety of these medications requires evaluation. Areas covered: Cardiovascular effects of these drug classes from preclinical and clinical data as well as non-cardiovascular safety issues are delineated from literature searches covering the last decade and up to June 2016. Major clinical trials assessing the cardiovascular safety of GLP-1 agonists (ELIXA and LEADER), DPP-4 inhibitors (SAVOR-TIMI 53, EXAMINE, and TECOS) and SGLT2 inhibitors (EMPA-REG OUTCOME) are reviewed and interpreted. Expert opinion: Based on review of the present evidence, these 3 classes of antihyperglycemic therapies have acceptably safe CV safety profiles for patients with type 2 diabetes. The latest evidence from LEADER and EMPA-REG OUTCOME trials indicate that liraglutide and empagliflozin have cardiovascular benefits that may prove to be of clinical importance in the management of type 2 DM.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2016) conducted a review in Type 2 diabetes mellitus. DPP4 inhibitors, GLP-1 analogs, and SGLT2 inhibitors was evaluated on Cardiovascular safety and benefits. DPP4 inhibitors, GLP-1 analogs, and SGLT2 inhibitors have acceptable CV safety profiles in type 2 diabetes, with liraglutide and empagliflozin showing cardiovascular benefits.
Synapse has enriched 10 related papers. Consider them for comparative context: